false0001613859 0001613859 2019-11-11 2019-11-11



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

FORM 8-K
 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date Earliest Event reported):
November 11, 2019
   
 
PRA Health Sciences, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
001-36732
 
46-3640387
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
  4130 ParkLake Avenue
Suite 400
Raleigh, NC 27612
(919) 786-8200
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each class
 
Name of exchange on which registered
 
Trading symbol
Common Stock $0.01 par value
 
Nasdaq Global Select Market
 
PRAH
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 





Item 5.02.                Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On November 11, 2019, Max Lin notified the board of directors (the “Board”) of PRA Health Sciences, Inc. (the “Company”) of his decision to step down as a member of the Board, effective immediately. Mr. Lin’s decision was not due to any disagreement with the Company’s management or Board. In addition, in connection with Mr. Lin’s departure, the Board elected to decrease the size of the Board to six members.

Item 9.01 Financial Statements and Exhibits.
 
Exhibit
 
Description of Document
104
 
Cover Page formatted in Inline XBRL







Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
 
 
 
PRA Health Sciences, Inc.
 
 
 
Date: November 15, 2019
By:
/s/ Michael J. Bonello
 
Name:
Michael J. Bonello
 
Title:
Executive Vice President and Chief Financial Officer